ACADIA Pharmaceuticals Inc. (ACAD) — Fair Value Analysis

Base-case fair value (P50): $32.96 · Current price: $22.40 · Verdict: Undervalued

The Verdict on ACAD

ACADIA PHARMACEUTICALS INC (ACAD) appears significantly undervalued based on our rigorous Monte Carlo simulations. The current market price of $22.40 stands well below our median fair value (P50) of $32.96, indicating a substantial potential upside of +47.1%. This robust projection suggests that, despite its present market valuation, ACAD possesses considerable room for appreciation. Our probabilistic framework points to a compelling opportunity, with the current trading price representing a significant discount against the company's intrinsic potential derived from thousands of forward-looking scenarios.

How ACAD stacks up against Healthcare

Within the dynamic Healthcare sector, ACADIA PHARMACEUTICALS INC (ACAD) maintains an average quality tier. This assessment evaluates its operational and financial health relative to sector peers, suggesting a balanced fundamental standing without extreme strengths or weaknesses. While an average quality tier provides a baseline, the pronounced +47.1% upside to its median fair value of $32.96 suggests that the market may be underappreciating ACAD's long-term potential. Investors should carefully weigh this average fundamental profile against the substantial discount indicated by our Monte Carlo analysis, noting that the fair value calculation accounts for such inherent characteristics.

What this means for investors

For investors evaluating ACADIA PHARMACEUTICALS INC (ACAD), the pronounced undervaluation signals a compelling opportunity. With a current price of $22.40 and a median fair value of $32.96, the market is currently pricing in a significant discount relative to our probabilistic assessment. Despite an average quality tier within the Healthcare sector, the Monte Carlo simulations indicate a robust +47.1% potential appreciation, suggesting a strong risk-reward profile for long-term holders. This analysis highlights that even for a company with an average operational and financial health, the discrepancy between market price and our fair value suggests a mispricing. To see the full bear/bull distribution and track ACAD's fair value as new fundamentals are released, sign up for a free FairCurve account.